9,351 Shares in GSK plc (NYSE:GSK) Bought by HB Wealth Management LLC

HB Wealth Management LLC purchased a new stake in GSK plc (NYSE:GSKFree Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 9,351 shares of the pharmaceutical company’s stock, valued at approximately $316,000.

Several other large investors have also recently bought and sold shares of the stock. Premier Path Wealth Partners LLC boosted its position in GSK by 21.1% during the fourth quarter. Premier Path Wealth Partners LLC now owns 34,274 shares of the pharmaceutical company’s stock worth $1,159,000 after purchasing an additional 5,967 shares during the period. Cypress Wealth Services LLC boosted its holdings in GSK by 23.8% in the 4th quarter. Cypress Wealth Services LLC now owns 11,966 shares of the pharmaceutical company’s stock valued at $405,000 after purchasing an additional 2,301 shares during the period. Advisors Management Group Inc. ADV raised its holdings in GSK by 6.1% in the 4th quarter. Advisors Management Group Inc. ADV now owns 91,530 shares of the pharmaceutical company’s stock valued at $3,096,000 after acquiring an additional 5,259 shares in the last quarter. San Luis Wealth Advisors LLC grew its stake in GSK by 37.8% during the fourth quarter. San Luis Wealth Advisors LLC now owns 21,968 shares of the pharmaceutical company’s stock worth $743,000 after buying an additional 6,031 shares in the last quarter. Finally, Ignite Planners LLC lifted its stake in GSK by 6.8% during the fourth quarter. Ignite Planners LLC now owns 18,965 shares of the pharmaceutical company’s stock worth $635,000 after purchasing an additional 1,210 shares during the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Stock Performance

Shares of GSK opened at $34.08 on Friday. The stock’s fifty day moving average price is $33.89 and its two-hundred day moving average price is $37.87. GSK plc has a 1 year low of $31.72 and a 1 year high of $45.92. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. The firm has a market cap of $70.63 billion, a PE ratio of 22.13, a PEG ratio of 1.32 and a beta of 0.63.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, January 9th. Shareholders of record on Friday, November 15th were issued a dividend of $0.3928 per share. This represents a $1.57 dividend on an annualized basis and a yield of 4.61%. The ex-dividend date of this dividend was Friday, November 15th. This is a positive change from GSK’s previous quarterly dividend of $0.38. GSK’s payout ratio is presently 96.10%.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on GSK shares. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and lowered their price target for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. StockNews.com downgraded shares of GSK from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Finally, Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Six analysts have rated the stock with a hold rating, one has issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $43.25.

Read Our Latest Stock Analysis on GSK

GSK Profile

(Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

Read More

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSKFree Report).

Institutional Ownership by Quarter for GSK (NYSE:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.